聚-4-羟基丁酸酯与合成及生物补片腹壁疝修补术后补片感染管理的回顾性比较
该回顾性综述比较了聚-4-羟基丁酸酯(Phasix)、合成补片和生物补片腹壁疝修补术后感染特征与管理。共407例患者,Phasix组感染6例、合成组7例、生物组2例。Phasix组感染患者风险因素比例更高,但无患者需补片取出,而合成组和生物组取出率分别为71.4%和50%(P=0.04)。作者认为结果属假设生成性。
要点
- Phasix补片感染多发生于高风险患者,但均未需补片取出。
- 合成补片感染后补片取出率71.4%,生物补片为50%。
- 三组在抗生素疗程、再入院率和住院时间上无显著差异。
核心结论
- 在本系列中,聚-4-羟基丁酸酯补片感染虽发生于更高风险患者,但均成功管理且无需补片取出。
- 因回顾性设计、样本量小和潜在选择偏倚,这些发现应视为假设生成而非优效性证据。
研究设计与样本
- 回顾性综述,纳入2014年至2025年接受腹壁疝修补术的患者。
- 共407例患者,其中Phasix补片47例,合成补片337例,生物补片23例。
- 主要结局包括感染率、微生物学、抗生素治疗、再入院、住院时间和干预需求。
- 评估了伤口分级、免疫抑制和既往补片感染等风险因素。
主要发现
- 补片感染发生例数:Phasix组6例,合成组7例,生物组2例。
- 感染患者中,Phasix组相比合成组和生物组有更高比例的风险因素:既往补片感染(33% vs. 0% vs. 0%)、CDC伤口分级≥3(83% vs. 29% vs. 0%)、免疫抑制(33% vs. 0% vs. 0%)。
- Phasix组感染细菌包括大肠埃希菌、奇异变形杆菌、嗜麦芽窄食单胞菌和肺炎克雷伯菌;合成组包括葡萄球菌属、屎肠球菌和链球菌;生物组为金黄色葡萄球菌。
- Phasix组平均抗生素治疗36天,合成组15天,生物组23天(p=0.25)。
- 再入院率分别为67%、86%和100%(p=0.56);平均住院时间分别为11天、9天和4天(p=0.4)。
临床怎么用
- 对于高风险患者(如既往补片感染、CDC伤口分级≥3、免疫抑制),Phasix补片感染后可能无需取出补片即可管理。
- 合成补片感染后补片取出率较高,临床需对此有所准备。
局限性
- 回顾性设计。
- 样本量小。
- 存在潜在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mesh infections are a feared complication of ventral hernia repair. This retrospective review compares infection characteristics and management among patients with poly-4-hydroxybutyrate (Phasix) and synthetic mesh while presenting biologic cases descriptively. METHODS: A retrospective review was conducted of patients undergoing ventral hernia repair from 2014 to 2025. Outcomes were evaluated among patients receiving Phasix, synthetic, or biologic mesh. Primary outcomes included infection rates, microbiology, antibiotic therapy, readmission, length of stay, and need for intervention. Risk factors such as wound class, immunosuppression, and prior mesh infection were assessed. RESULTS: A total of 407 patients underwent ventral hernia repair with Phasix (n = 47), synthetic (n = 337), and biologic (n = 23) mesh. Mesh infections developed in six patients with Phasix, seven with synthetic, and two with biologic. Of the people with mesh infections, the Phasix group demonstrated higher rates of risk factors compared to the synthetic and biologic groups: pre-existing mesh infections (33% vs. 0% vs. 0%), CDC wound class ≥ 3 (83% vs. 29% vs. 0%), and immunosuppression (33% vs. 0% vs. 0%). The bacterial profile of these mesh infections includes E. coli, Proteus mirabilis, Stenotrophomonas maltophilia, and Klebsiella pneumoniae in the Phasix group, Staphylococcus, Enterococcus faecium, and Streptococcus in the synthetic group, and Staph aureus in the biologic group. Phasix infections required a mean of 36 days of antibiotic therapy versus 15 days for synthetic and 23 days for biologic mesh (p = 0.25). Readmission rates were 67, 86, and 100%, respectively (p = 0.56). Mean hospital stays were 11, 9, and 4 days (p = 0.4). No Phasix patients required mesh excision, whereas 71.4% of synthetic mesh patients and 50% of biologic mesh patients underwent mesh explantation (p = 0.04). CONCLUSION: Infections involving poly-4-hydroxybutyrate mesh were successfully managed without mesh explantation in this series despite occurring in higher-risk patients. Because of the retrospective design, small sample size, and potential selection bias, these findings should be considered hypothesis-generating rather than evidence of superiority.
引用
- Dickerson K, Akkihal KS, Ittiruck A, et al. Comparison of mesh infection management following ventral hernia repair with poly-4-hydroxybutyrate, synthetic, and biologic mesh: a retrospective review. Surg Endosc. 2026. PMID: 42864463. doi:10.1007/s00464-026-13480-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。